Readings for 12/5

Three Interesting Things:
1.) I find it interesting that Big Data has been there for a while and there is a mass amount of it but yet it has just started being used. The solution to the healthcare industry's problem has been right in front of them but they struggled to grasp it and convert it to useful knowledge.
2.) I think that it is interesting that an underlying problem continuously brought up in class is the "fee for service" model that is currently in the system. This problem leads to malpractice of medicine as well as over use of treatment in order to make a quick buck. Having Big Data will allow for the industry to defer from this and provide the care that is needed for the specific patient and the physicians will be compensated on this. The more positive outcomes they have the more money they will make. This will decrease medical errors and sending which will ultimately aid the systems defaults now.
3.) I think it is interesting that clinical trials have had such limitations that hinder their success. This is in terms of the small population they can use for their trials as well as the lack of outcome information they receive. This is what drives the fact that they take so long because they do not have the proper information they need to understand their patients and how they pair with certain drugs. They have to go with the flow and figure it out as they go which is why this drug development process can take up to 15 years to finish. If they had more access to extended RWD/RWE then they would know this information before hand which could cut down their costs and timing tremendously.

Three Questions:
1.) How do you get access to Big Data? Where is it? Is it an open platform? Who owns it?
2.) How does Big Data tackle the privacy issue?
3.) Can pharmacies or physician use Big Data to figure out when a patient should seek out MTM?
4.) How do RWE and Big Data differ? Is RWE a subset of Big Data?
5.) What other systems does the 92% of data left to find reside in other than EHR?


Comments

Post a Comment

Popular posts from this blog

Readings for 11/21

Three Interesting Things: 1.) I think it is interesting that some patients avoid treating their pain with opioids because of the negative connotation given by the media surrounding these drugs. Although, yes, they can be addictive there are ways to manage the intake so that you can both treat your pain and not become addicted. 2.) I think that the fact that patients could have to sign a narcotic contract to ensure that they will not go to fill the prescription at another pharmacy. I think that this is an excessive way to do this but I also feel that this is the only way to keep patients honest because of people within these situations these people cannot control their need. 3.) I think that it is interesting that this article brings up the topic of having pharmacists be more intuned with their work and be more educating for their patients. We have talked about often how pharmacists should have more of a comforting position with their patients and be able to have empathy for them. ...
Read more

Reading for 9/24

Three Interesting Things: 1.) I had no idea that the term "Clinical Research" only applied to studies and trials done on humans rather then animals or other test subjects. When grouping them all together you tend to have a broader or less abstract view of what the study actually entails but breaking down the term makes you start to separate the trial in your mind ahead of time. 2.) I think it is interesting that the FDA approves and regulates drug advertising but yet some companies still get away with falsifying their information about a drug when advertising it. There have been a multitude of law suits where patients experience a side affect or undesired outcome due to advertisements lacking certain information. With the most regulatory group approving all of this it is funky that some still slip through the cracks. 3.) I think that when it comes to naming drugs there is a laboratory name and then a manufacturing name. Its basically further splitting up the industry in...
Read more

Reflection 10/27

This week we learned about Federal Regulation with Dr. Baker. When it comes to regulation there is much to take in because there are many boxes to check state and federal wise. The US is one of the most efficient countries when it comes to regulating the drugs brought to market. The reason for doing so is because with healthcare resources being so scarce, there is no room for medical errors. This means that the regulatory committees want to get drugs to patients that are safe and effective that will not cause controversy in the future. The FDA's job is to decide what is actually considered a drug, whether this drug is going to need a prescription or can be over the counter, double check marketing efforts of the drug, and then finally make sure that all drugs that need proper FDA documentation have it. To those trying to experiment with drugs, they may see this process to be over bearing but it is specifically put in place to make sure that patients are receiving proper care. The ov...
Read more